Forte Biosciences (FBRX) Change in Account Payables (2016 - 2026)
Forte Biosciences' (FBRX) quarterly Change in Account Payables came in at $3.1 million in Q1 2026, up 435.47% year-on-year from $578000.0 in Q1 2025, and down 31.18% on a QoQ basis from $4.5 million in Q4 2025.
Forte Biosciences (FBRX) Change in Account Payables (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Change in Account Payables data on file, last reported at $3.1 million in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 435.47% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $8.1 million, a 141.46% increase from a year earlier, with the FY2025 full-year figure at $5.5 million, up 83.48% from the prior year.
- Change in Account Payables for Q1 2026 stood at $3.1 million, down from $4.5 million in the prior quarter.
- Over the last five years, Change in Account Payables for FBRX reached as high as $4.5 million in Q4 2025 and fell as low as -$3.9 million in Q4 2023.
- Historically, Change in Account Payables has averaged $713941.2 across 5 years, with a median of $261000.0 in 2024.
- On a YoY basis, Change in Account Payables climbed as much as 1689.25% in 2023 and fell as far as 21577.78% in 2023.
- Year by year, Change in Account Payables stood at $18000.0 in 2022, then sank by 21577.78% to -$3.9 million in 2023, then soared by 81.53% to -$714000.0 in 2024, then surged by 729.83% to $4.5 million in 2025, then tumbled by 31.18% to $3.1 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $3.1 million in Q1 2026, $4.5 million in Q4 2025, and $558000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - | 3.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.10 Mn |
| Mar 31, 2026 | 3.10 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 558,000.00 |
| Sep 30, 2025 | 558,000.00 |
| Jun 30, 2025 | -90,000.00 |
| Jun 30, 2025 | -90,000.00 |
| Mar 31, 2025 | 578,000.00 |
| Mar 31, 2025 | 578,000.00 |
| Dec 31, 2024 | -714,000.00 |
| Dec 31, 2024 | -714,000.00 |
| Sep 30, 2024 | -116,000.00 |
| Sep 30, 2024 | -116,000.00 |
| Jun 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | 3.59 Mn |
| Mar 31, 2024 | 261,000.00 |
| Mar 31, 2024 | 261,000.00 |
| Dec 31, 2023 | -3.87 Mn |
| Dec 31, 2023 | -3.87 Mn |